Providence Saint Mary Regional Cancer Center

Summary

Providence Saint Mary Regional Cancer Center is a medical facility located in Walla Walla, Washington. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Cancer and other specialties. Providence Saint Mary Regional Cancer Center is involved with conducting 212 clinical trials across 392 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.

Top PIs

Clinical Trials running at Providence Saint Mary Regional Cancer Center

Ovarian Cancer

Lung Cancer

Breast Cancer

Prostate Cancer

Bladder Cancer

Breast cancer

Esophageal cancer

Pancreatic Cancer

Multiple Myeloma

Bladder Carcinoma

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.

Recruiting

1 award

Phase 2

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria